Annual Report 2022

MANAGEMENT DISCUSSION AND ANALYSIS 15 The United Laboratories International Holdings Limited Annual Report 2022 Litigations Reference is made to the Company’s announcements dated 9 August 2019, 14 August 2019 and 9 November 2022 in relation to the investment and cooperation agreement with 恒大地產集團成都有限公司 (Evergrande Real Estate Group (Chengdu) Limited) (“Evergrande (Chengdu)”). The Group applied for the commencement of an action against, among others, Evergrande (Chengdu) on 7 March 2022 in the Guangzhou Intermediate People’s Court for recovery of the outstanding consideration receivables of approximately RMB340 million and relevant damages and received a notice of acceptance on 14 March 2022 (the “Action”). Due to the large number of actions against China Evergrande Group commenced in the Guangzhou Intermediate People’s Court, the Action is handled by the Chengdu Intermediate People’s Court. After accepting the case, the Chengdu Intermediate People’s Court heard the case in the first session on 21 February 2023, and as some legal procedures had not been completed in this trial, the Court will continue the trial at a separate schedule. The Company will make further announcement(s) on the progress of the Action as and when appropriate. Save for the above, there was no other material litigations during the Year. PURCHASE, REDEMPTION OR SALE OF LISTED SECURITIES OF THE COMPANY During the year ended 31 December 2022, the Company has repurchased a total of 12,464,000 shares on the Stock Exchange at total consideration (including transaction costs) of approximately HK$51,534,000. All the repurchased shares were subsequently cancelled. Particulars of the repurchases are as follows: Purchase Price Month No. of Shares Highest Lowest Total Consideration HK$ HK$ HK$ January 3,324,000 4.60 4.38 14,786,000 February – – – – March 3,068,000 4.10 3.95 12,310,000 April 5,524,000 4.10 4.00 22,684,000 May to August – – – – September 4,000 3.20 3.20 13,000 October 544,000 3.20 3.17 1,741,000 November and December – – – – Save for the above, neither the Company, nor any of its subsidiaries purchased, sold or redeemed any of the listed securities of the Company during the year ended 31 December 2022.